Lilly Closes Its Singapore Drug Discovery Center; Is China Discovery Unit In The Works?
This article was originally published in The Pink Sheet Daily
Executive Summary
The decision is part of a broader corporate R&D restructuring plan, and Lilly will continue some of its priority projects at its Indianapolis headquarters.
You may also be interested in...
Empire State Of Mind: Lilly Aims To Build Academic Ties With N.Y. Research Center
Eli Lilly & Co. gained a foothold in New York with its acquisition of ImClone Systems Inc. in 2008. Now it's looking to make more of a splash in the city and strengthen ties with local academic powerhouses by taking up residence in a new state-of-the-art biotech facility.
Empire State Of Mind: Lilly Aims To Build Academic Ties With N.Y. Research Center
Eli Lilly & Co. gained a foothold in New York with its acquisition of ImClone Systems Inc. in 2008. Now it's looking to make more of a splash in the city and strengthen ties with local academic powerhouses by taking up residence in a new state-of-the-art biotech facility.
China's Second-largest CRO Seeks Initial Public Offering In The U.S.
Seeking to join top competitor WuXi PharmaTech on the New York Stock Exchange, ShangPharma, the second-largest contract research organization in China, is looking to raise an estimated $89.9 million in an initial public offering expected to debut the week of Oct. 18